Sökning: onr:"swepub:oai:DiVA.org:liu-168560" >
Should we accept a ...
Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian arguments
-
- Juth, Niklas (författare)
- Karolinska Institutet,Karolinska Inst, Sweden
-
- Henriksson, Martin (författare)
- Linköpings universitet,Avdelningen för samhälle och hälsa,Medicinska fakulteten
-
- Gustavsson, Erik (författare)
- Linköpings universitet,Avdelningen för filosofi, historia, konst och religion,Filosofiska fakulteten
-
visa fler...
-
- Sandman, Lars (författare)
- Linköpings universitet,Avdelningen för samhälle och hälsa,Medicinska fakulteten
-
visa färre...
-
(creator_code:org_t)
- 2020-07-20
- 2021
- Engelska.
-
Ingår i: Bioethics. - : WILEY. - 0269-9702 .- 1467-8519. ; 35:4, s. 307-314
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- In recent years, the issue of accepting a higher cost per health improvement for orphan drugs has been the subject of discussion in health care policy agencies and the academic literature. This article aims to provide an analysis of broadly egalitarian arguments for and against accepting higher costs per health improvement. More specifically, we aim to investigate which arguments one should agree upon putting aside and where further explorations are needed. We identify three kinds of arguments in the literature: considerations of substantial equality, formal equality, and opportunity cost. We argue that considerations of substantial equality do not support higher costs per health improvement orphan drugs, even if such considerations are considered valid. On the contrary, arguments of formal equality may support accepting a higher cost per health improvement for orphan drugs. However, in order to do so, a number of both normative and empirical issues must be resolved; these issues are identified in the article. For instance, it must be settled to what extent the opportunity cost in terms of foregone health for other patients is acceptable in order to uphold formal equality. We conclude that certain arguments can be set aside, and future focus should be put on the unresolved normative and empirical issues related to formal equality and opportunity cost.
Ämnesord
- HUMANIORA -- Filosofi, etik och religion -- Filosofi (hsv//swe)
- HUMANITIES -- Philosophy, Ethics and Religion -- Philosophy (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Samhällsfarmaci och klinisk farmaci (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Social and Clinical Pharmacy (hsv//eng)
Nyckelord
- cost-effectiveness; drug prices; equality; health economics; opportunity cost; orphan drugs; priority setting
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas